Vamil Divan
Stock Analyst at Guggenheim
(4.63)
# 220
Out of 4,711 analysts
216
Total ratings
64.34%
Success rate
16.91%
Average return
Main Sectors:
Stocks Rated by Vamil Divan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KROS Keros Therapeutics | Downgrades: Neutral | n/a | $17.03 | - | 4 | Dec 16, 2024 | |
| PFE Pfizer | Maintains: Buy | $35 → $33 | $26.36 | +25.19% | 19 | Dec 11, 2024 | |
| RVNC Revance Therapeutics | Maintains: Neutral | $6.66 → $3.1 | $3.09 | +0.32% | 6 | Dec 10, 2024 | |
| ABSI Absci | Reiterates: Buy | $10 | $2.99 | +234.45% | 2 | Dec 3, 2024 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $156 → $162 | $144.47 | +12.13% | 11 | Nov 6, 2024 | |
| ABBV AbbVie | Maintains: Buy | $212 → $221 | $175.58 | +25.87% | 22 | Nov 6, 2024 | |
| VERA Vera Therapeutics | Maintains: Buy | $56 → $64 | $42.60 | +50.23% | 4 | Oct 28, 2024 | |
| TVTX Travere Therapeutics | Maintains: Buy | $23 → $41 | $17.18 | +138.65% | 7 | Oct 9, 2024 | |
| PROK ProKidney | Initiates: Buy | $6 | $1.51 | +297.35% | 1 | Sep 10, 2024 | |
| INSM Insmed | Maintains: Buy | $70 → $95 | $70.44 | +34.87% | 4 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.53 | - | 2 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $77 | $53.35 | +44.33% | 8 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $20 | $5.61 | +256.51% | 9 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $26 | $0.36 | +7,064.51% | 2 | Jun 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $9 | $1.00 | +800.09% | 2 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $0.84 | - | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $19 | $16.87 | +12.63% | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $95 → $98 | $135.42 | -27.63% | 8 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $34 | $29.71 | +14.44% | 13 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $2.38 | +320.17% | 3 | May 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $49 | $90.73 | -45.99% | 3 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $315 → $356 | $767.76 | -53.63% | 17 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $6 | $3.49 | +71.92% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $144 → $154 | $36.26 | +324.71% | 9 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 | $10.89 | +37.74% | 5 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $26.76 | - | 6 | Dec 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | n/a | $22.09 | - | 13 | Jul 10, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $81 | $98.05 | -17.39% | 12 | Oct 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $15 | $4.99 | +200.60% | 4 | Aug 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $58 → $61 | $57.33 | +6.40% | 8 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $103 | $2.19 | +4,603.20% | 3 | Jan 17, 2018 |
Keros Therapeutics
Dec 16, 2024
Downgrades: Neutral
Price Target: n/a
Current: $17.03
Upside: -
Pfizer
Dec 11, 2024
Maintains: Buy
Price Target: $35 → $33
Current: $26.36
Upside: +25.19%
Revance Therapeutics
Dec 10, 2024
Maintains: Neutral
Price Target: $6.66 → $3.1
Current: $3.09
Upside: +0.32%
Absci
Dec 3, 2024
Reiterates: Buy
Price Target: $10
Current: $2.99
Upside: +234.45%
Johnson & Johnson
Nov 6, 2024
Maintains: Neutral
Price Target: $156 → $162
Current: $144.47
Upside: +12.13%
AbbVie
Nov 6, 2024
Maintains: Buy
Price Target: $212 → $221
Current: $175.58
Upside: +25.87%
Vera Therapeutics
Oct 28, 2024
Maintains: Buy
Price Target: $56 → $64
Current: $42.60
Upside: +50.23%
Travere Therapeutics
Oct 9, 2024
Maintains: Buy
Price Target: $23 → $41
Current: $17.18
Upside: +138.65%
ProKidney
Sep 10, 2024
Initiates: Buy
Price Target: $6
Current: $1.51
Upside: +297.35%
Insmed
Jul 9, 2024
Maintains: Buy
Price Target: $70 → $95
Current: $70.44
Upside: +34.87%
Jun 18, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.53
Upside: -
Apr 23, 2024
Reiterates: Buy
Price Target: $77
Current: $53.35
Upside: +44.33%
Sep 7, 2023
Maintains: Neutral
Price Target: $19 → $20
Current: $5.61
Upside: +256.51%
Jun 15, 2023
Reiterates: Buy
Price Target: $26
Current: $0.36
Upside: +7,064.51%
Apr 3, 2023
Maintains: Buy
Price Target: $8 → $9
Current: $1.00
Upside: +800.09%
Mar 1, 2023
Initiates: Neutral
Price Target: n/a
Current: $0.84
Upside: -
Aug 10, 2022
Maintains: Neutral
Price Target: $27 → $19
Current: $16.87
Upside: +12.63%
Aug 8, 2022
Maintains: Neutral
Price Target: $95 → $98
Current: $135.42
Upside: -27.63%
Jul 28, 2022
Maintains: Buy
Price Target: $36 → $34
Current: $29.71
Upside: +14.44%
May 25, 2022
Maintains: Buy
Price Target: $20 → $10
Current: $2.38
Upside: +320.17%
May 3, 2022
Maintains: Buy
Price Target: $51 → $49
Current: $90.73
Upside: -45.99%
May 2, 2022
Maintains: Buy
Price Target: $315 → $356
Current: $767.76
Upside: -53.63%
Mar 16, 2022
Maintains: Buy
Price Target: $8 → $6
Current: $3.49
Upside: +71.92%
Mar 3, 2022
Maintains: Buy
Price Target: $144 → $154
Current: $36.26
Upside: +324.71%
May 6, 2021
Upgrades: Buy
Price Target: $15
Current: $10.89
Upside: +37.74%
Dec 13, 2019
Downgrades: Neutral
Price Target: n/a
Current: $26.76
Upside: -
Jul 10, 2019
Assumes: Neutral
Price Target: n/a
Current: $22.09
Upside: -
Oct 11, 2018
Maintains: Outperform
Price Target: $71 → $81
Current: $98.05
Upside: -17.39%
Aug 15, 2018
Assumes: Outperform
Price Target: $15
Current: $4.99
Upside: +200.60%
Jul 27, 2018
Maintains: Neutral
Price Target: $58 → $61
Current: $57.33
Upside: +6.40%
Jan 17, 2018
Initiates: Outperform
Price Target: $103
Current: $2.19
Upside: +4,603.20%